Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice
Beatriz Escudero-Pérez, Paula Ruibal, Monika Rottstegge, Anja Lüdtke, Julia R. Port, Kristin Hartmann, Sergio Gómez-Medina, Jürgen Müller-Guhl, Emily V. Nelson, Susanne Krasemann, Estefanía Rodríguez, César Muñoz-Fontela
Beatriz Escudero-Pérez, Paula Ruibal, Monika Rottstegge, Anja Lüdtke, Julia R. Port, Kristin Hartmann, Sergio Gómez-Medina, Jürgen Müller-Guhl, Emily V. Nelson, Susanne Krasemann, Estefanía Rodríguez, César Muñoz-Fontela
View: Text | PDF
Research Article Infectious disease Virology

Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice

  • Text
  • PDF
Abstract

Filoviruses of the genus Ebolavirus include 6 species with marked differences in their ability to cause disease in humans. From the highly virulent Ebola virus to the seemingly nonpathogenic Reston virus, case fatality rates can range between 0% and 90%. In order to understand the molecular basis of these differences, it is imperative to establish disease models that recapitulate human disease as faithfully as possible. Nonhuman primates (NHPs) are the gold-standard models for filovirus pathogenesis, but comparative studies are skewed by the fact that Reston virus infection can be lethal for NHPs. Here we used HLA-A2–transgenic, NOD–scid–IL-2γ receptor–knockout (NSG-A2) mice reconstituted with human hematopoiesis to compare Ebola virus and Reston virus pathogenesis in a human-like environment. While markedly less pathogenic than Ebola virus, Reston virus killed 20% of infected mice, a finding that was linked to exacerbated inflammation and viral replication in the liver. In addition, the case fatality ratios of different Ebolavirus species in humans were recapitulated in the humanized mice. Our findings point to humanized mice as a putative model to test the pathogenicity of newly discovered filoviruses, and suggest that further investigations on Reston virus pathogenesis in humans are warranted.

Authors

Beatriz Escudero-Pérez, Paula Ruibal, Monika Rottstegge, Anja Lüdtke, Julia R. Port, Kristin Hartmann, Sergio Gómez-Medina, Jürgen Müller-Guhl, Emily V. Nelson, Susanne Krasemann, Estefanía Rodríguez, César Muñoz-Fontela

×

Figure 2

Comparative ebolavirus pathogenesis in huNSG-A2 mice.

Options: View larger image (or click on image) Download as PowerPoint
Comparative ebolavirus pathogenesis in huNSG-A2 mice.
(A) Kaplan-Meier s...
(A) Kaplan-Meier survival curves of infected mice. Mice were infected intranasally with 1000 FFU EBOV (n = 14), RESTV (n = 15), TAFV (n = 11), BDBV (n = 7), and SUDV (n = 7). Mock-infected mice (n = 11) received 20 μL PBS. Log-rank (Mantel-Cox) analysis indicated statistically significant differences between results for EBOV- and SUDV-infected mice and those for all the other groups (P < 0.0001). (B) Weight loss of infected huNSG-A2 mice. Nonparametric Kruskal-Wallis analysis followed by Dunn’s post hoc test analysis indicated significant differences between results for mice infected with EBOV (P = 0.025) and SUDV (P = 0.017) and those for the other groups. (C) Kinetics of viremia in surviving and nonsurviving mice from infection to experimental endpoint. Dotted lines represent the limit of detection of 50 FFU/mL. (D) Levels of AST in blood of infected mice (survivors and nonsurvivors). In the survivor group,the mock treatment group is represented by the black dashed line. (E) Survival curve of huNSG-A2 mice infected with the EBOV variants Mayinga (n = 8) and Makona (n = 7). Log-rank (Mantel-Cox) analysis indicated statistical significance (P = 0.042). (F) Kinetics of viremia from infection to experimental endpoint. Dotted lines represent the limit of detection of 50 FFU/mL. Throughout the figure, error bars represent mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts